Taken together, our data indicate that both BRD7 and BIRC2 might be involved in the malignant progression of NPC and targeting the BRD7/BIRC2 axis might be a promising strategy for the clinical diagnosis and treatment of NPC. Here, BRD7 is linked to nasopharyngeal carcinoma.